冠昊生物
(300238)
| 流通市值：35.93亿 | | | 总市值：35.93亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 278,135,520.4 | 189,698,181.61 | 91,441,252.36 | 404,178,697.25 |
| 营业收入 | 278,135,520.4 | 189,698,181.61 | 91,441,252.36 | 404,178,697.25 |
| 二、营业总成本 | 249,921,949.86 | 160,966,865.61 | 71,751,172.33 | 360,489,232.61 |
| 营业成本 | 59,418,347.34 | 42,079,822.97 | 20,070,872.09 | 84,366,507.09 |
| 税金及附加 | 2,856,459.25 | 1,948,613.09 | 853,805.68 | 4,367,281.13 |
| 销售费用 | 118,255,574.23 | 73,734,951.86 | 30,734,582.38 | 166,536,462.51 |
| 管理费用 | 40,650,655.56 | 26,766,060.42 | 12,473,774.86 | 55,366,142.27 |
| 研发费用 | 28,093,493.13 | 16,028,573.85 | 7,484,200.53 | 44,503,865.82 |
| 财务费用 | 647,420.35 | 408,843.42 | 133,936.79 | 5,348,973.79 |
| 其中:利息费用 | 459,933.35 | 313,083.35 | 159,791.67 | 1,782,364.35 |
| 其中:利息收入 | 470,015.14 | 275,495.58 | 130,992.97 | 1,502,794.74 |
| 加:投资收益 | 805,725.68 | -404,010.79 | -129,015.63 | -3,640,197.33 |
| 资产处置收益 | 1,470 | 885 | 1,090 | 924,105.58 |
| 资产减值损失(新) | 35,412.54 | 113,559.74 | 264,385.52 | -3,890,692.8 |
| 信用减值损失(新) | -6,460,317.84 | -4,437,590.41 | -524,388.33 | -9,278,234.44 |
| 其他收益 | 8,901,376.79 | 2,052,158.25 | 1,218,321.8 | 6,184,116.15 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 31,497,237.71 | 26,056,317.79 | 20,520,473.39 | 33,988,561.8 |
| 加:营业外收入 | 11,592.96 | 2,285.03 | 270.15 | 11,171.24 |
| 减:营业外支出 | 174,832.72 | 180,190.86 | 40,325.66 | 1,910,538.58 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 31,333,997.95 | 25,878,411.96 | 20,480,417.88 | 32,089,194.46 |
| 减:所得税费用 | 10,675,074.65 | 9,119,075.73 | 5,005,638.04 | 11,016,656.94 |
| 六、净利润 | 20,658,923.3 | 16,759,336.23 | 15,474,779.84 | 21,072,537.52 |
| 持续经营净利润 | 20,658,923.3 | 16,759,336.23 | 15,474,779.84 | 21,072,537.52 |
| 归属于母公司股东的净利润 | 27,836,338.53 | 20,148,444.33 | 14,391,514.75 | 31,005,798.58 |
| 少数股东损益 | -7,177,415.23 | -3,389,108.1 | 1,083,265.09 | -9,933,261.06 |
| (一)基本每股收益 | 0.1 | 0.08 | 0.05 | 0.12 |
| (二)稀释每股收益 | 0.1 | 0.08 | 0.05 | 0.12 |
| 八、其他综合收益 | -112,095.04 | -41,348.81 | -80,925.93 | 4,244,210.95 |
| 归属于母公司股东的其他综合收益 | -112,095.04 | -41,348.81 | -80,925.93 | 4,244,210.95 |
| 九、综合收益总额 | 20,546,828.26 | 16,717,987.42 | 15,393,853.91 | 25,316,748.47 |
| 归属于母公司股东的综合收益总额 | 27,724,243.49 | 20,107,095.52 | 14,310,588.82 | 35,250,009.53 |
| 归属于少数股东的综合收益总额 | -7,177,415.23 | -3,389,108.1 | 1,083,265.09 | -9,933,261.06 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-26 | 2024-03-06 |
| 审计意见(境内) | | | | 标准无保留意见 |